Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Shareholder Meeting (November 2024)
18 slides from Recce Pharmaceuticals's shareholder meeting presentation, Nov 6, 2024
Slide 1: CEO Presentation
CEO Presentation ASX:RCE | FSE:R9Q November 2024
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre
Slide 3: About Recce Pharmaceuticals Ltd
About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives • Australian clinical-stage biotech company, with a United States presence • Qualified Infectious Disease Product designation – 10 years of market exclusivity plus fa
Slide 4: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman Michele Dilizia – Executive Director & Chief Scientific BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,
Slide 5: Company Overview
Company Overview Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – 4th November 2024 RCE Share Price and Volume Chart – 12 Months ASX & FSE Code RCE, R9Q 2,500,000 $0.80 Share Price AUD $0.445 $0.70 2,000,000 3-Month
Slide 6: At our last AGM – 2023/2024 Corporate Goals
At our last AGM – 2023/2024 Corporate Goals Data Review and Completion of Clinical Trials Successfully streamline and accelerate current clinical trial processes in chosen indications and routes of administration Government/Private Enterprise Partnerships Funding, research partnerships, licensing, g
Slide 7: Data Review and Completion of Clinical Trials
Data Review and Completion of Clinical Trials Successfully streamline and accelerate current clinical trial processes in chosen indications and routes of administration Completed Clinical Trials Upcoming Clinical Trial Milestones • 20 of 30 patients dosed - in final Phase I • Complete 80 subject dat
Slide 8: Phase II ABSSSI Clinical Trial – Dosing in Final Stages
Phase II ABSSSI Clinical Trial – Dosing in Final Stages Efficacy Data and Safety Approval Received NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES • Non-Data Safety Monitoring Board unanimously agree R327G is safe and well-tolerated in patients – demonstrating highly encoura
Slide 9: Large Addressable Market
Large Addressable Market The global diabetic foot infection (DFI) and sepsis market is worth in excess of $US9.5 billion Global Diabetic Foot Infections (DFI) Market NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES • The DFI treatment market is estimated to be worth ~US$5.2 b
Slide 10: Government/Private Enterprise Partnerships
Government/Private Enterprise Partnerships Funding, research partnerships, licensing, grant submissions, military areas of interest Domestic Partnerships & Funding Global Partnerships & Funding Awarded AusIndustry Advanced Overseas (R&D) Memorandum of Understanding (MoU) with PT Finding Etana Biotec
Slide 11: Build out Presence in the USA
Build out Presence in the USA Further expand capabilities in USA supporting FDA strategy Active Engagement in US Focused Conferences and Landmarks • Opening Keynote Address and Opening R&D Address at the World Anti-microbial Resistance Congress • Presented at US BIO 2024, the largest and most compre
Slide 12: RECCE® 327 – Global Recognition
RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio
Slide 13: Global Regulatory Strategy
Global Regulatory Strategy Expansion into Indonesia • Pursuing similar regulatory pathway in Indonesia • Leveraging MoU with PT Etana to facilitate local regulatory process • Successfully completing Phase III registrational trial in Indonesia, enabling Recce to replicate regulatory approval for R327
Slide 14: Strategic Opportunity in South-East Asia
Strategic Opportunity in South-East Asia to Accelerate Clinical Program • Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies, supporting the Indonesian Government’s access to novel infectious disease medicines • Significantly progressed regulatory s
Slide 15: Top 20 Shareholders Movements since last AGM
Top 20 Shareholders Movements since last AGM – Increased Support 1-Nov-24 Position Holder/Group Name Issued Capital (%) Balance 1 Nov 24 1 Graham Melrose And Olga Melrose 34,828,311 15.02% 2 Hsbc Custody Nominees (Australia) Limited 14,946,039 6.45% 3 M Rogers And A Veliss 10,200,000 4.40% 4 Mr Jame
Slide 16: Recce’s Commercialisation Pathway
Recce’s Commercialisation Pathway Indonesia DFI Phase III Clinical Trial NDA Submission Clinical Phase II Data Programs H224 DFI & ABSSSI NDA Submission Australia & US ABSSSI/DFI Phase III Clinical Trial 2024 2025 2026 2027 2028 15
Slide 17: Summary – Significant Value Creating Opportunities
Summary – Significant Value Creating Opportunities Phase II Acute Bacterial Skin and Skin Structure Infection clinical trial to be clinically completed CY24 Indonesian Phase III registrational clinical trial data read-out and regulatory submission expected in late 2025, potential market approval and
Slide 18: Thank you
Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q recce.com.au 17
Recce Pharmaceuticals — Shareholder Meeting (November 2024) on 6ix